Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS

NCT05140811 is registered in ClinicalTrials.gov with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. as lead sponsor.

NCT NCT05140811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05140811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS
Lead sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 5, 2022
Completion date
March 1, 2024
Enrollment
126 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndromes